AANEM 2026: Navigating an Expanding MG Treatment Landscape

Previewing the 2026 MGFA Scientific Session at AANEM, Amanda L. Hernandez, MD, PhD, discusses the expanding myasthenia gravis (MG) treatment landscape and the need for individualized approaches to treatment selection, response assessment, and sequencing. She highlights recent data with intravenous efgartigimod, an FcRn antagonist, from the phase 3 ADAPT SERON trial in AChR antibody-seronegative generalized MG, including triple-seronegative disease.Dr Hernandez also identifies BAFF/APRIL-targeted approaches and investigational CD19-directed CAR T-cell therapies as emerging areas of interest and notes that inebilizumab, an FDA-approved CD19-directed B cell-depleting monoclonal antibody, is already available as another CD19-targeted therapeutic approach. As treatment options multiply, she emphasizes the need for practical strategies to select therapy, measure meaningful response, and navigate sequencing or transitions between treatments.